-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, KUXtEBrCwodtmQOxSmj3M6H0yQc3ForcV9Rfyd4RdV3yWT9k/+Rtz5eFWPOe0O/n eDqphAajJZE5M2uBAU5LsA== 0001144204-05-035767.txt : 20051115 0001144204-05-035767.hdr.sgml : 20051115 20051115084506 ACCESSION NUMBER: 0001144204-05-035767 CONFORMED SUBMISSION TYPE: 13F-HR PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20050930 FILED AS OF DATE: 20051115 DATE AS OF CHANGE: 20051115 EFFECTIVENESS DATE: 20051115 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BAKER BROS ADVISORS LLC CENTRAL INDEX KEY: 0001263508 IRS NUMBER: 134093645 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 13F-HR SEC ACT: 1934 Act SEC FILE NUMBER: 028-10519 FILM NUMBER: 051204640 BUSINESS ADDRESS: STREET 1: 667 MADISON AVENUE STREET 2: 17TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10021 BUSINESS PHONE: 2125212418 13F-HR 1 v029391_13fhr.txt UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 13F FORM 13F COVER PAGE Report for the Calendar Year or Quarter Ended: September 30, 2005 Check here if Amendment [ ]; Amendment Number: _____ This Amendment (Check only one.): [ ] is a restatement. [ ] adds new holdings entries. Institutional Investment Manager Filing this Report: Name: Baker Bros. Advisors, LLC -------------------------------------------- Address: 667 Madison Avenue, 17th Floor -------------------------------------------- New York, NY 10021-8029 -------------------------------------------- Form 13F File Number: 28-10519 The institutional investment manager filing this report and the person by whom it is signed hereby represent that the person signing the report is authorized to submit it, that all information contained herein is true, correct and complete, and that it is understood that all required items, statements, schedules, lists, and tables, are considered integral parts of this form. Person Signing this Report on Behalf of Reporting Manager: Name: Leo Kirby -------------------------------------------- Title: Chief Financial Officer -------------------------------------------- Phone: 212-521-2418 -------------------------------------------- Signature, Place, and Date of Signing: /s/ Leo Kirby New York, N.Y. November 14, 2005 - -------------------------- --------------------------- ---------------------- [Signature] [City, State] [Date] Report Type (Check only one.): [X] 13F HOLDINGS REPORT. (Check here if all holdings of this reporting manager are reported in this report.) [_] 13F NOTICE. (Check here if no holdings reported are in this report, and all holdings are reported by other reporting manager(s).) [_] 13F COMBINATION REPORT. (Check here if a portion of the holdings for this reporting manager are reported in this report and a portion are reported by other reporting manager(s).) List of Other Managers Reporting for this Manager: None FORM 13F SUMMARY PAGE Report Summary: Number of Other Included Managers: 0 ----------- Form 13F Information Table Entry Total: 63 ----------- Form 13F Information Table Entry Value: 683,594 ----------- (thousands) List of Other Included Managers: None
COLUMN 1 COLUMN 2 COLUMN 3 COLUMN 4 COLUMN 5 COLUMN 6 COLUMN 7 COLUMN 8 TITLE OF VALUE SHRS OR SH/ PUT/ INVESTMENT OTHER VOTING AUTHORITY NAME OF ISSUER CLASS CUSIP (x$1000) PRN AMT PRN CALL DISCRETION MANAGERS SOLE SHARED NONE - ----------------- ----- ----- -------- ------- --- ---- ---------- -------- ---- ------ ---- Acadia Pharmaceuticals Inc. COM 004225108 7,571 665,904 SH SOLE 665,904 Adolor Corp. COM 00724X102 11,389 1,066,397 SH SOLE 1,066,397 Alexion Pharmaceuticals Inc. COM 015351109 6,099 220,564 SH SOLE 220,564 Allos Therapeutics Inc. COM 019777101 6,948 2,847,418 SH SOLE 2,847,418 American Pharmaceuticals Ptn. COM 02886P109 2,688 58,860 SH SOLE 58,860 Amylin Pharmaceuticals Inc. COM 032346108 59,901 1,721,801 SH SOLE 1,721,801 Anadys Pharmaceuticals Inc. COM 03252Q408 4,204 393,958 SH SOLE 393,958 Arena Pharmaceuticals Inc. COM 040047102 927 93,609 SH SOLE 93,609 Array Biopharma Inc. COM 04269X105 2,909 405,174 SH SOLE 405,174 Autoimmune Inc. COM 052776101 24 26,100 SH SOLE 26,100 Barrier Therapeutics Inc. COM 06850R108 1,094 130,348 SH SOLE 130,348 Biocryst Pharmaceuticals Inc. COM 09058V103 22,925 2,344,036 SH SOLE 2,344,036 Coley Pharmaceutical Group Inc. COM 19388P106 10,025 550,830 SH SOLE 550,830 Corcept Therapeutics Inc. COM 218352102 500 100,000 SH SOLE 100,000 Critical Therapeutics Inc. COM 22674T105 6,781 719,856 SH SOLE 719,856 Cubist Pharmaceuticals Inc. COM 229678107 12,695 589,355 SH SOLE 589,355 Curis Inc. COM 231269101 123 26,800 SH SOLE 26,800 Cytokinetics Inc. COM 23282W100 800 98,300 SH SOLE 98,300 Dynavax Technologies Corp. COM 268158102 128 19,100 SH SOLE 19,100 Encysive Pharmaceuticals Inc. COM 29256X107 853 72,397 SH SOLE 72,397 Incyte Corp. COM 45337C102 15,576 3,314,070 SH SOLE 3,314,070 Inhibitex Inc. COM 45719T103 27,096 2,662,695 SH SOLE 2,662,695 Insmed Inc. COM 457669208 44 33,135 SH SOLE 33,135 Intermune Inc. COM 45884X103 4,157 251,180 SH SOLE 251,180 Intrabiotics Pharmaceuticals COM 46116T506 4,040 1,103,934 SH SOLE 1,103,934 Ithaka Acquisition Corporation COM 465707206 395 65,000 SH SOLE 65,000 Ligand Pharmaceuticals Inc. CL B 53220K207 268 38,357 SH SOLE 38,357 Martek Bioscience Corp. COM 572901106 1,851 52,684 SH SOLE 52,684 Medarex Inc. COM 583916101 11,431 1,200,694 SH SOLE 1,200,694 Metabasis Therapeutics Inc. COM 59101M105 2,902 497,710 SH SOLE 497,710 Momenta Pharmaceuticals Inc. COM 60877T100 884 32,457 SH SOLE 32,457 Monogram Biosciences Inc. COM 60975U108 937 398,619 SH SOLE 398,619 Myogen Inc. COM 62856E104 3,460 147,215 SH SOLE 147,215 Myriad Genetics Inc. COM 62855J104 3,631 166,100 SH SOLE 166,100 Nastech Pharmaceutical Inc. COM 631728409 1,607 113,680 SH SOLE 113,680 Neose Technologies Inc. COM 640522108 1,356 576,923 SH SOLE 576,923 Neurocrine Bioscience Inc. COM 64125C109 467 9,500 SH SOLE 9,500 Neurogen Corp. COM 64124E106 36,643 5,325,999 SH SOLE 5,325,999 Nuvelo Inc. COM 67072M301 10,658 1,110,215 SH SOLE 1,110,215 Onyx Pharmaceuticals Inc. COM 683399109 6,173 247,200 SH SOLE 247,200 Panacos Pharmaceuticals Inc. COM 69811Q106 154 15,800 SH SOLE 15,800 Pharmacyclics Inc. COM 716933106 4,684 519,288 SH SOLE 519,288 Pozen Inc. COM 73941U102 4,399 400,298 SH SOLE 400,298 Praecis Pharmaceuticals Inc. COM 739421105 24 50,100 SH SOLE 50,100 Renovis Inc. COM 759885106 4,059 300,000 SH SOLE 300,000 Seattle Genetics Inc. COM 812578102 6,273 1,194,927 SH SOLE 1,194,927 Senomyx Inc. COM 81724Q107 11,105 652,111 SH SOLE 652,111 Telik Inc. COM 87959M109 7,395 452,041 SH SOLE 452,041 Theravance Inc. COM 88338T104 8,645 410,869 SH SOLE 410,869 Trimeris Inc. COM 896263100 55,260 3,602,369 SH SOLE 3,602,369 Vertex Pharmaceuticals Inc. COM 92532F100 12,706 568,519 SH SOLE 568,519 Viropharma Inc. COM 928241108 152,083 7,311,700 SH SOLE 7,311,700 Xcyte Therapies Inc. PFD CV EXCH 98389F408 354 95,500 SH SOLE 95,500 Xenoport Inc. COM 98411C100 4,541 275,221 SH SOLE 275,221 Zymogenetics Inc. COM 98985T109 12,977 786,464 SH SOLE 786,464 Alexion Pharmaceuticals Notes 1.375% 2/01/2012 CONV BONDS 015351AF6 45,881 43,800,000 PRN SOLE 43,800,000 Decode Genetics Notes 3.5% 4/15/2011 CONV BONDS 243586AB0 2,591 3,000,000 PRN SOLE 3,000,000 Encysive Pharmaceuticals Notes 2.5% 3/15/2012 CONV BONDS 29256XAB3 5,077 4,750,000 PRN SOLE 4,750,000 Incyte Genomics Notes 3.5% 2/15/2011 CONV BONDS 45337CAE2 14,298 19,000,000 PRN SOLE 19,000,000 Intermune Inc Notes .25% 3/01/2011 CONV BONDS 45884XAC7 5,243 6,000,000 PRN SOLE 6,000,000 Medarex Inc Notes 2.25% 5/15/2011 CONV BONDS 583916AG6 13,706 15,000,000 PRN SOLE 15,000,000 Regeneron Conv Notes 5.5% 10/17/08 CONV BONDS 75886FAB3 14,044 14,822,000 PRN SOLE 14,822,000 Viropharma Incorporated Notes 6% 3/01/2007 CONV BONDS 928241AC2 5,938 5,975,000 PRN SOLE 5,975,000
-----END PRIVACY-ENHANCED MESSAGE-----